Cutaneous reactions to epidermal growth factor receptor inhibitors

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Antineoplastic therapy utilizing epidermal growth factor receptor (EGFR) inhibitors frequently leads to cutaneous toxicities.
• Skin reactions, including papular/pustular follicular eruptions, xerosis, pruritus, and nail/hair abnormalities, are common within two weeks of treatment initiation.
• The incidence and severity of these skin toxicities often correlate with clinical efficacy but can significantly impair health-related quality of life.

Purpose of the Study:

• To review the common cutaneous toxicities associated with EGFR inhibitor therapy.
• To discuss the impact of these skin reactions on treatment adherence and quality of life.
• To highlight the need for evidence-based treatment strategies for EGFR inhibitor-induced skin eruptions.

Main Methods:

• Review of existing literature on EGFR inhibitor-induced cutaneous toxicities.
• Analysis of reported clinical manifestations and their association with treatment outcomes.
• Evaluation of current management recommendations based on anecdotal evidence and clinical experience.

Main Results:

• Cutaneous toxicities are the most prevalent adverse effects of EGFR inhibitors.
• Skin reactions can necessitate treatment interruption, dose reduction, or discontinuation.
• Current treatment recommendations lack robust evidence from randomized controlled trials.

Conclusions:

• EGFR inhibitor-induced skin eruptions are a significant clinical challenge.
• Management strategies currently rely on limited evidence, primarily anecdotal reports.
• Randomized controlled trials are essential for developing evidence-based treatment paradigms for these toxicities.